$Progyny (PGNY.US)$Listed in 2019, the revenue has continued...
$Progyny (PGNY.US)$Listed in 2019, the revenue has continued to grow rapidly after listing, with an average growth rate of 51% in the past 3 years. Operating profit has been affected by the rapid increase in expenses, showing a decline in 2020 and 2022, with an average growth rate of 34.1% in the past 3 years. The net profit in 2022 contracted by 54%, lower than the level in 2020.
Revenue in the first half of 2023 increased by 46.4%. Operating profit increased by 2.4 times to 0.03 billion, affected by the slower growth of expenses. Net profit increased by 1.4 times to 0.033 billion.
The balance sheet shows that accounts receivable increased by 0.19 billion in the past 3 years, while the cumulative net profit was only 0.14 billion. The accounts receivable of 0.24 billion also accounts for 30.5% of the annual revenue, which is relatively high. The debt ratio is 31.1% and there is no interest-bearing debt.
In the past 3 years, the net cash flow from operations has been higher than the net cash flow from investments, generating a certain amount of shareholder surplus.
Currently, the PE ratio is 109, and the TTM PE ratio is 66.8. If the net income reaches 0.07 billion for the whole year, the PE ratio will decrease to 44.6. It can be observed for several more quarters.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more